Previous 10 | Next 10 |
PLANO, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that researchers at NYU Grossman School of Medicine (“NY...
Blackstone ( BX -2.1% ) says its Blackstone Life Sciences V was oversubscribed and final close is at its hard cap of $4.6B of total capital commitments, making it the largest life sciences private fund raised till date. More news on: The Blackstone Group Inc., Alnylam Pharmaceuticals, ...
PLANO, Texas, July 07, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the expansion of its leadership team and the appointment of sev...
PLANO, Texas, June 24, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the receipt of $350 million related to the closing of its previously announced strat...
Gainers: Wah Fu Education (NASDAQ: WAFU ) +257% . More news on: Wah Fu Education Group Limited, Wins Finance Holdings Inc., Celldex Therapeutics, Inc., Stocks on the move, , Read more ...
Wah Fu Education (NASDAQ: WAFU ) +405% . More news on: Wah Fu Education Group Limited, DarioHealth Corp., Ambow Education Holding Ltd., Stocks on the move, , Read more ...
Reata Pharmaceuticals (NASDAQ: RETA ) announces a $350M royalty and equity investment from funds managed by Blackstone Life Sciences earmarked to advance bardoxolone methyl through clinical trials and potential commercialization. More news on: Reata Pharmaceuticals, Inc., Healthcare stoc...
FINANCING WILL ADVANCE BARDOXOLONE AS THE FIRST POTENTIAL THERAPY FOR ALPORT SYNDROME, AS WELL AS CONTINUE DEVELOPMENT FOR OTHER RARE AND SERIOUS FORMS OF CHRONIC KIDNEY DISEASE REATA’S CASH GUIDANCE UPDATED: RUNWAY EXTENDED THROUGH END OF 2023 REATA TO HOST CONFERENCE...
Image source: The Motley Fool. Reata Pharmaceuticals, Inc. (NASDAQ: RETA) Q1 2020 Earnings Call May 11, 2020 , 4:30 p.m. ET Operator Continue reading
Reata Pharmaceuticals, Inc. (RETA) Q1 2020 Earnings Conference Call May 11, 2020, 16:30 ET Company Participants Vineet Jindal - VP, Corporate Communications & Strategy Colin Meyer - Chief Medical Officer & EVP, Product Development Manmeet Soni - CFO & EVP Warren Huf...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...